Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic and Pharmacodynamic Effects of Dorzagliatin in Pancreatic Insufficient-Cystic Fibrosis
NCT06995651Phase 1Recruiting
- Sponsor
- Michael R. Rickels
- Start
- Oct 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dorzagliatin in cystic fibrosis-related diabetes (CFRD) (2 arms), sponsored by Michael R. Rickels. Primary endpoints: Maximum Plasma Concentration at 2 months and Glucose tolerance at 2 months. Started Oct 2025; status: recruiting.
02
Drugs
dorzagliatin
03
Conditions
cystic fibrosis-related diabetes (CFRD)
Beyond the preview
Go deeper on NCT06995651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06995651.